KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare.
Exit since Feb. 2011. Purchaser: Evotec AG
Evotec acquires Kinaxo, Profitable Exit for Seed-Investor High-Tech Gründerfonds
Evotec expands its drug discovery platform with cutting-edge technologies Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs. Strengthening Evotec’s position as quality leader in drug discovery The acquisition of Kinaxo confirms Evotec’s leading position as fully integrated drug discovery and
Am Klopferspitz 19a
21. Jul 2006 – 09. Feb 2011